Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities

Peptides, Год журнала: 2025, Номер 187, С. 171380 - 171380

Опубликована: Март 11, 2025

Recent studies with peptide-based incretin herapies have focussed mainly on the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide and dual tirzepatide that engages receptors for GLP-1 glucose-dependent insulinotropic polypeptide (GIP). Randomised clinical trials 'real-world' confirmed marked glucose-lowering weight-lowering efficacy of these agents across diverse populations. These include different ethnic groups, young elderly individuals without diabetes and/or overweight or obesity. also protections against development progression cardiovascular renal diseases are additive to benefits conferred by improved control blood glucose body weight. Emerging evidence suggests therapies could additionally ameliorate fatty liver disease, chronic inflammation, sleep apnea possibly degenerative bone disorders cognitive decline. New incretin-based peptide in a long-acting glucagon (LY3324954), GLP-1/glucagon agonists (survodutide, pemvidutide, mazdutide, G49), triple GLP-1/GIP/glucagon (retatrutide, efocipegtrutide), combination amylin analogue cagrilintide (CagriSema), unimolecular GLP-1/amylin (amycretin), GIP antibody agonism (MariTide). The creation multi-targeting synthetic peptides provides opportunities management type 2 obesity as well new therapeutic approaches an expanding list associated co-morbidities. aim review is acquaint reader developments field from 2023 present (February 2025).

Язык: Английский

---

Impact of medical versus surgical weight loss on cardiovascular outcomes

Trends in Cardiovascular Medicine, Год журнала: 2025, Номер unknown

Опубликована: Март 1, 2025

Язык: Английский

---

The Effects of Oral Semaglutide on Hepatic Fibrosis in Subjects with Type 2 Diabetes in Real-World Clinical Practice: A Post Hoc Analysis of the Sapporo-Oral SEMA Study

Pharmaceuticals, Год журнала: 2025, Номер 18(1), С. 129 - 129

Опубликована: Янв. 19, 2025

Background/Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) is an important common comorbidity in subjects with type 2 diabetes, and fibrosis a factor directly related to its prognosis. Glucagon-like peptide-1 receptor agonists are useful treatment options for MASLD; however, the efficacy of oral semaglutide treating steatosis/fibrosis has not been fully elucidated. Methods: A secondary analysis multicenter, retrospective, observational study investigating safety Japanese diabetes real-world clinical setting (the Sapporo-Oral SEMA study) was conducted. Subjects original cohort were divided into groups as follows: suspected MASLD (alanine aminotransferase > 30 U/L) placed overall group; subpopulation from group at high risk hepatic (fibrosis-4 (FIB-4) index ≥ 1.3 or platelet count < 200,000/µL) high-risk remaining low-risk group. Changes steatosis FIB-4 after induction explored using paired t-test Wilcoxon signed-rank test. Results: Overall, 169 (including 131 that switched other medications) analyzed, 67 102 selected groups, respectively. Oral significantly improved (from 46.1 44.6, p 0.001) 1.04 0.96, well several metabolic parameters all cohorts. The confirmed by addition of, switching from, existing agent groups. Furthermore, improvement negatively correlated baseline index. Conclusions: might be option fibrosis, even when conventional medications diabetes.

Язык: Английский

---

Therapeutic Potential of GLP-1 Receptor Agonists in Metabolic Associated Steatotic Liver Disease

Annals of Pharmacotherapy, Год журнала: 2025, Номер unknown

Опубликована: Март 12, 2025

Objective: To summarize the current knowledge on therapeutic potential of GLP-1 receptor agonists in managing metabolic associated steatotic liver disease (MASLD). Data Sources: A literature review was conducted using search terms , MASLD NAFLD nonalcoholic fatty treatment and therapy PubMed (from January 1, 2019, through February 2025), National Institutes Health (NIH) Scopus World Organization (WHO) data. Study Selection Extraction: All relevant clinical trials, articles, package inserts, guidelines evaluating clinically evidence regarding were considered for inclusion. Synthesis: RAs have shown promising results treatment. Semaglutide has demonstrated efficacy reducing fat content, inflammation, fibrosis, with trials indicating improvements hepatic biomarkers cardiometabolic risk factors. Similarly, tirzepatide been substantial weight loss significant reductions fibrosis markers. Both agents exert their effects mechanisms involving improved insulin sensitivity, reduced lipid accumulation, attenuation inflammation. Relevance to Patient Care Clinical Practice: Given high prevalence patients obesity type 2 diabetes, semaglutide could play a critical role practice by addressing multiple facets disease. fat, improving biomarkers, mitigating risks, which are leading causes morbidity mortality patients. Incorporating these therapies into significantly enhance patient outcomes targeting both liver-related systemic complications Conclusions: GLP1 show great promoting loss, glycemic control,

Язык: Английский

---

Management of Atherosclerotic Cardiovascular Risk in Inflammatory Bowel Disease: Current Perspectives

Advances in Therapy, Год журнала: 2025, Номер unknown

Опубликована: Март 27, 2025

Inflammatory bowel disease (IBD) is a complex condition characterized by inflammation of the gastrointestinal system, encompassing Crohn's and ulcerative colitis. Patients diagnosed with IBD have an increased risk atherosclerotic cardiovascular disease. This heightened can be attributed to combination mechanisms, including traditional factors, chronic inflammation, intestinal dysbiosis, thrombosis, use certain medications such as corticosteroids. There are significant gaps in current knowledge, particularly regarding management factors for prevention. Similarly, effects specific therapies, newer ones, not yet fully understood. review focuses on epidemiological evidence linking It describes potential pathophysiological mechanisms underlying this association examines challenges involved accurately assessing these patients, utility complementary tools subclinical atherosclerosis detection. Additionally, we consider therapeutic implications managing patients. Finally, also underscores importance multidisciplinary collaboration. Effective teamwork among gastroenterologists, cardiologists, general practitioners essential providing comprehensive care patients IBD.

Язык: Английский

---

ANMCO statement: semaglutide in the cardio-nephro-metabolic continuum

European Heart Journal Supplements, Год журнала: 2025, Номер 27(Supplement_5), С. v247 - v255

Опубликована: Май 1, 2025

Semaglutide, a glucagon-like peptide-1 receptor agonist, has emerged as pivotal therapeutic agent in the management of cardio-renal-metabolic continuum. Initially developed for glycaemic control Type 2 diabetes mellitus, its benefits extend far beyond glucose regulation. Clinical trials have demonstrated semaglutide's potential to reduce major adverse cardiovascular events, particularly overweight/obese patients with high risk, well improving functional capacity suffering from heart failure preserved left ventricular function. Additionally, it shown promise renal outcomes, such slowing progression albuminuria and reducing risk chronic kidney disease diabetic populations. These effects are likely due multifaceted mechanisms, including anti-inflammatory properties, weight reduction, blood pressure lowering, direct protection. This review synthesizes current evidence on role interrelated domains cardiovascular, renal, metabolic health.

Язык: Английский

---

Semaglutide as a Possible Therapy for Healthy Aging: Targeting the Hallmarks of Aging

Ageing Research Reviews, Год журнала: 2024, Номер 102, С. 102582 - 102582

Опубликована: Ноя. 14, 2024

Язык: Английский

---